Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZD1839 in Advanced Transitional Cell Carcinoma of the Urothelium
NCT00014144Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Feb 2001
- Primary completion
- May 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in transitional cell carcinoma of the urothelium (TCC), sponsored by SWOG Cancer Research Network. Primary endpoint: Progression-Free Survival Rate up to 3 years. Started Feb 2001; status: completed.
02
Drugs
03
Conditions
transitional cell carcinoma of the urothelium (TCC)
Beyond the preview
Go deeper on NCT00014144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00014144.